TIDMEAH

RNS Number : 9411O

Eco Animal Health Group PLC

15 June 2022

13 June 2022

ECO Animal Health Group plc

("ECO", the "Company" or the "ECO Group") (AIM: EAH)

Partnership with Imperial College London

saRNA technology to deliver swine vaccines and biologics

ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that its wholly owned subsidiary, ECO Animal Health Ltd, has entered into a research partnership with Professor Robin Shattock at Imperial College London, to assess the veterinary application of the novel self-amplifying RNA (saRNA) technology. The scope of the collaboration will be the delivery of vaccine antigens and biologics to pigs against three important infectious disease targets (two viral and one bacterial).

saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for a longer time period, resulting in higher protein levels per dose. This has the potential to allow saRNAs to be delivered at lower concentrations than conventional mRNA therapeutics, leading to less frequent or lower dosing, lower costs and a much broader range of potential applications. The saRNA platform aims to underpin the next generation of RNA-delivered medicines enabling not only vaccines but also a broad range of therapeutic applications, for example conditions where immune modulation is beneficial.

ECO will use its validated swine disease models to generate proof of concept data within one year, with the view of selecting candidates for development, registration and commercialisation under license from Imperial College London.

The diseases targeted with this technology are among the most economically damaging to the swine industry which amounts to nearly 800 million pigs worldwide and represents 36% of total meat consumption.

David Hallas, Chief Executive of ECO said : "This is a very exciting collaboration for ECO and a great credit to our R&D team for having successfully concluded the agreement with Imperial College. The global market potential for products developed from this partnership is very significant and, if successful, would be a major step in ECO's longer term strategy to develop new and innovative products alongside Aivlosin."

Professor Robin Shattock of Imperial College said : "I am pleased to be working with the team at ECO on this exciting project. saRNA technology has very significant potential in animal health as it can be delivered in much lower doses than is currently possible and hence represents the next generation of RNA delivered medicines."

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR") as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

For further information please contact:

 
 ECO Animal Health Group plc 
  David Hallas (CEO) 
  Christopher Wilks (CFO)                       020 8447 8899 
 
   IFC Advisory 
   Graham Herring 
   Zach Cohen                                     020 3934 6630 
 
   Singer Capital Markets (Nominated Adviser 
   & Joint Broker) 
   Mark Taylor 
   George Tzimas                                  020 7496 3000 
 
   Investec (Joint Broker) 
   Gary Clarence 
   Alex Penney                                    020 7597 5970 
   Carlo Spingardi 
 
   Peel Hunt LLP (Joint Broker) 
   Dr Christopher Golden 
   James Steel                                    020 7418 8900 
 
 
 Equity Developments 
  Hannah Crowe 
  Matt Evans            020 7065 2692 
 

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSFFSMIEESEDM

(END) Dow Jones Newswires

June 15, 2022 02:35 ET (06:35 GMT)

Eco Animal Health (LSE:EAH)
Gráfica de Acción Histórica
De Jul 2022 a Ago 2022 Haga Click aquí para más Gráficas Eco Animal Health.
Eco Animal Health (LSE:EAH)
Gráfica de Acción Histórica
De Ago 2021 a Ago 2022 Haga Click aquí para más Gráficas Eco Animal Health.